Denali Therapeutics Inc.
NEWS
Noubar Afeyan, founder of Flagship Pioneering and Moderna, spoke at an event hosted by the Institute of Global Health Innovation.
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.
Flagship will pour in $75 million into Vesalius to support its beginnings, while Rondo raised $67 million to support the development of its preclinical pipeline.
The planned testing for DNL919 was held back pending additional documentation required to initiate the studies and information on the preclinical toxicology assessment.
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Today, Noubar Afeyan, founder of Flagship Pioneering, published the platform development company’s 2022 Annual Letter, and in it, outlined what he sees as the four top forces shaping the future of biotech.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
Denali Therapeutics announced that the FDA had placed a clinical hold on the IND application for DNL919 and would receive an official clinical hold letter from the agency in about 30 days.
JOBS
IN THE PRESS